Thomas Koelblen

Thomas Koelblen, M.Sc.

Research Assistant Scientist

Department: Pharmacodynamics
Business Email: t.koelblen@ufl.edu

About Thomas Koelblen

Thomas Koelblen is a Research Assistant Scientist in the Department of Pharmacodynamics. He graduated a B.S. in biotechnologies from University Paris-Sud at Orsay in 2009, then a M.Sc. from the University Paris-Sorbonne, Ecole Pratique des Hautes Etudes (EPHE) in 2011. During his M.Sc., he worked at the French National Institute for health and Medical Research (INSERM) where he studied how variations in the 5’ UnTranslated Region (5’UTR) were affecting the translational regulation of HIV structural genes. After graduating, he joined the French National Center of Scientific Research (CNRS) as Research Engineer in biochemistry and biophysics from 2012 to 2017. His research focus was to characterize the structure of Brucella’s virulence factor (Btp1), and to investigate the molecular mechanisms involved in the interaction between the infected human cells and Helicobacter pylori’s type IV secretion systems. He then moved to the US in 2017 to joined Dr. Burris’s team at Saint Louis University school of Medicine, then Washington University in Saint Louis, and now University of Florida.

Koelblen is leading research on multiple Nuclear Receptors (NRs) responsible of the regulation of metabolism in humans. NRs are ligand regulated transcription factors, making them key targets to treat human diseases such as diabetes, obesity, or Alzheimer’s disease. His focus is to produces pure NRs ligand binding domains, and to develop new biochemical assays to screen innovative molecules on those targets. His work led to numbers of collaboration with other academic institutions (Dartmouth, Washington University in Saint Louis, Maastricht University, Tulane University), and with multiple pharmaceutical companies (Pelagos pharmaceuticals, Myonid Therapeutics, Asteroid Therapeutics).

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-4760-2602

Publications

2024
From Functional Fatty Acids to Potent and Selective Natural-Product-Inspired Mimetics via Conformational Profiling.
ACS central science. 10(2):477-486 [DOI] 10.1021/acscentsci.3c01155. [PMID] 38435518.
2022
Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists.
ACS chemical biology. 17(5):1143-1154 [DOI] 10.1021/acschembio.2c00057. [PMID] 35417135.
2022
Progress toward the De Novo Asymmetric Synthesis of Euphanes.
Organic letters. 24(20):3686-3690 [DOI] 10.1021/acs.orglett.2c01299. [PMID] 35584298.
2022
Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB.
Nature communications. 13(1) [DOI] 10.1038/s41467-022-34892-4. [PMID] 36414641.
2021
Naturally Occurring Genetic Variants in the Oxytocin Receptor Alter Receptor Signaling Profiles.
ACS pharmacology & translational science. 4(5):1543-1555 [DOI] 10.1021/acsptsci.1c00095. [PMID] 34661073.
2020
The Orphan Nuclear Receptor TLX Is a Receptor for Synthetic and Natural Retinoids.
Cell chemical biology. 27(10):1272-1284.e4 [DOI] 10.1016/j.chembiol.2020.07.013. [PMID] 32763139.
2017
Molecular dissection of protein-protein interactions between integrin α5β1 and the Helicobacter pylori Cag type IV secretion system.
The FEBS journal. 284(23):4143-4157 [DOI] 10.1111/febs.14299. [PMID] 29055076.
2014
The Brucella TIR domain containing proteins BtpA and BtpB have a structural WxxxE motif important for protection against microtubule depolymerisation.
Cell communication and signaling : CCS. 12 [DOI] 10.1186/s12964-014-0053-y. [PMID] 25304327.
2013
Structure of the Toll/interleukin 1 receptor (TIR) domain of the immunosuppressive Brucella effector BtpA/Btp1/TcpB.
FEBS letters. 587(21):3412-6 [DOI] 10.1016/j.febslet.2013.09.007. [PMID] 24076024.

Contact Details

Emails:
Business:
t.koelblen@ufl.edu
Addresses:
Business Mailing:
PO Box 103610
GAINESVILLE FL 32611